Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827
Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803–827
António Araújo
Read
1404
Timeswas read the article
714
Total PDF
690
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 22 | 17 | 39 |
| 2025 5 | 77 | 45 | 122 |
| 2025 4 | 53 | 33 | 86 |
| 2025 3 | 44 | 24 | 68 |
| 2025 2 | 35 | 33 | 68 |
| 2025 1 | 29 | 33 | 62 |
| 2024 12 | 12 | 23 | 35 |
| 2024 11 | 33 | 45 | 78 |
| 2024 10 | 34 | 25 | 59 |
| 2024 9 | 25 | 28 | 53 |
| 2024 8 | 44 | 33 | 77 |
| 2024 7 | 23 | 28 | 51 |
| 2024 6 | 19 | 26 | 45 |
| 2024 5 | 26 | 30 | 56 |
| 2024 4 | 18 | 19 | 37 |
| 2024 3 | 24 | 14 | 38 |
| 2024 2 | 23 | 28 | 51 |
| 2024 1 | 15 | 27 | 42 |
| 2023 12 | 15 | 20 | 35 |
| 2023 11 | 12 | 30 | 42 |
| 2023 10 | 12 | 33 | 45 |
| 2023 9 | 24 | 30 | 54 |
| 2023 8 | 12 | 13 | 25 |
| 2023 7 | 17 | 28 | 45 |
| 2023 6 | 12 | 14 | 26 |
| 2023 5 | 20 | 24 | 44 |
| 2023 4 | 10 | 11 | 21 |
Show all
